chrisvoncsefalvay/vaers-outcomes huggingface dataset:
More than 35 days in between Moderna Covid-19 vaccinations.; tenderness in right arm injection site/ soreness in right arm injection site; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (More than 35 days in between Moderna Covid-19 vaccinations.) and VACCINATION SITE PAIN (tenderness in right arm injection site/ soreness in right arm injection site) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unknown) for COVID-19 vaccination.     No Medical History information was reported.    On 31-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (More than 35 days in between Moderna Covid-19 vaccinations.) and VACCINATION SITE PAIN (tenderness in right arm injection site/ soreness in right arm injection site). At the time of the report, PRODUCT DOSE OMISSION ISSUE (More than 35 days in between Moderna Covid-19 vaccinations.) had resolved and VACCINATION SITE PAIN (tenderness in right arm injection site/ soreness in right arm injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.     No concomitant medications were reported.   Treatment medication were not reported.   Reporter did not allow further contact
There is a fluid filled 'sack' that almost looks like a small blister, but is not a blister, located about one inch under the injection site. This fluid filled sack is about one-third of an inch long by one-fourth of an inch wide.
On 5/9/01, approx. 23 hours, post vax, she began to vomit continuously. She does not go to daycare and had not been around any sick people. She vomited approx. every 5 minutes and refused anything per mouth. She did not have a fever after the 2nd time she vomited. I arrived at her pediatrician's office about 20 minutes after this started and she was running a fever of 102F (she has never run a fever this high before) and her color was a greenish/white. She was lethargic and her breathing was very rapid. Her pediatrician told us to go straight to the ER. She was still vomiting and listless and her eyes were rolling back in her head. She was choking when she was trying to vomit. She had to receive fluids at the ER through IV, as she was dehydrated. She was released approx. 6 hours later, after having IV for 4 hours. It took 45 minutes and 2 sites to start the IV. Rubber banks were tied around her upper arms to prepare each arm for the IV (to check veins). Then again tied to draw the blood for the blood work. These bands were on her injection sites from the day before, making this procedure extremely painful. Her fever stayed at 102F for 1 day. She still tried to vomit for 4 days. She stayed weak for about a week and an half. The blood work at the hospital showed no evidence of an infection-normal WBC. It only showed that she was dehydrated. As far as we know at this time, she has recovered.
60 y/o male, BMI 33.4, PMHx of GERD, ulcerative colitis, admitted for SOB on 10/17/21. Pt tested positive on 10/10/21 but did not experience SOB until 10/14/21. Chest x-ray completed on 10/17/21 showed scattered linear opacities that may represent subsegmental atelectasis or developing atypical pneumonia. CT on 10/17/21 also showed diffuse bilateral groundglass opacities most consistent with multifocal pneumonitis. Covid was treated with remdesivir and supportive measures. Pt was discharged home with home health on 10/27/21.
This spontaneous report was received from a registered nurse and refers to a 12-year-old patient of unknown gender. The patient's pertinent medical history, drug reactions or allergies and concomitant medications were not reported. On 19-DEC-2018, the patient was vaccinated with improperly stored dose of GARDASIL 9 lot # 1586752, expiration date 16-FEB-2021 (dose and route of administration were not reported). Administered dose of vaccine experienced the temperature excursion of 31.1 Fahrenheit degrees (F) (below 32 F/ 0 Celsius degrees) (30 cycles) for 35 hours 30 minutes. There were no previous excursions reported. The digital data logger was involved to capture the temperature excursion. No adverse effects were reported. This is one of multiple reports received from the same reporter (it was reported that it was unknown which lot numbers of each specific vaccine were administered to which patient).; Sender's Comments: US-009507513-1901USA000071:
On 2/23/00, the pt experienced numbness and tingling in her face. A physician did not evaluate her.
This case was reported by a other health professional via sales rep and described the occurrence of pain in a female patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received SHINGRIX at an unknown dose. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced pain, headache, fatigue, erythema and swelling. On an unknown date, the outcome of the pain, headache, fatigue, erythema and swelling were unknown. It was unknown if the reporter considered the pain, headache, fatigue, erythema and swelling to be related to SHINGRIX. Additional details were provided as follows: The case was received by the office manager. The age at vaccination was not reported. The patient was in her 60's. At the time of report, therapy dates and onset date were not known.
Throbbing pain; tingling fingers in left arm; pain going up the neck of left side; fever; chills; joint pain (both shoulders, low back, hips, and knee); loss of appetite; fatigue; weakness; headache; muscle pain; This is a spontaneous report from a contactable Other HCP (patient). This 40-year-old female patient (not pregnant) received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) via Intramuscular on 08Jan2021 on Arm left at single dose (Lot # 3249) for covid-19 immunisation. Medical history included Osteoporosis, vitamin D deficient. No known allergies. No other vaccine in four weeks. Concomitant medications included other medications in two weeks. She experienced throbbing pain and tingling fingers in left arm, pain going up the neck of left side. Also experience typical side effects: fever, chills, joint pain (both shoulders, low back, hips, and knee), loss of appetite, fatigue, weakness, headache, and muscle pain on 09Jan2021. No Covid prior vaccination. No covid tested post vaccination. No treatments received. Outcome of the events was recovering.
R09.02 HYPOXIA 2/13/2022 ABNL CHEST CT SCAN R09.02 HYPOXIA 2/13/2022 LONG TERM METHADONE THERAPY FOR DRUG MAINTENANCE THERAPY
Baby "stiffned" and large amount of "foamy mucus" from mouth and nose, Followed by projectile vomiting. Call to doctor, Pt to CR for evaluation with resulting admission
Swelling to Face; Shortness of Breath; Initial Report Received on 03-Jun-2020.  Non-significant information received on 30-Jun-2020:  confirmation from the reporter that no additional information is or will be available.  A pharmacy technician reported that a 32 year-old female (race and ethnicity not rovided) received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization and the patient developed "swelling of the face and shortness of breath".  No relevant medical history was reported. The patient is allergic to penicillin and cephalosporin.   No relevant concomitant medications were reported.  On 28-May-2020, the patient received the first dose of HEPLISAV-B (Lot #933094, expiration date 17-Apr-2021, NDC # not reported) to the left deltoid. Concomitant vaccines administered include the second dose of Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) administered to the right deltoid on the same day.  The patient had previously received her first dose of Gardasil 9 on 01-Mar-2020 without event.   On 03-Jun-2020, 7 days after having been vaccinated with HEPLISAV-B, the patient called the pharmacy, stating that she had developed "swelling of the face and shortness of breath" on that day. The pharmacy staff directed the patient to seek medical care and to contact her Primary Care Physician.   At the time of the report, the outcome of the event was not reported.  Company comment: The company assessed the events as non-serious.; Sender's Comments: The company assessed the events as non-serious.
COVID positive today; COVID positive today; This is a spontaneous report from a contactable other health professional, the patient. A 25-year-old male patient had received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), dose 1 intramuscular, administered in Arm left on 28Dec2020 at 13:00 (Lot number: UNKNOWN) (at the age of 25 years-old) as a single dose and dose 2 intramuscular, administered in Arm left on 16Jan2021 (Lot number: UNKNOWN) as a single dose for COVID-19 immunization. The patient medical history were not reported. Concomitant medications included none. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medications in two weeks. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 03Mar2021, at 08:00, the patent had COVID positive. The events resulted in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The patient underwent lab tests and procedures which included COVID-19 nasal swab test on 03Mar2021 showed positive. The patient did not receive any treatment for the events. The outcome of the event Covid-19 was recovering and other event was unknown.  No follow-up attempts are possible. Information about lot/batch number cannot be obtained.; Sender's Comments: The efficacy of a drug varies from patient to patient and can be affected by different factors; however, a contributory role of the suspect product BNT162B2 to the reported vaccination failure / COVID-19 cannot be ruled out.
after receiving 2 doses of the Moderna COVID-19 Vaccine had 2 blood test and said that has No antibodies what so ever; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION FAILURE (after receiving 2 doses of the Moderna COVID-19 Vaccine had 2 blood test and said that has No antibodies what so ever) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 016M20A and 025L20A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included SIMVASTATIN, LEVOTHYROXINE, TRAMADOL and OMEPRAZOLE for an unknown indication.   On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VACCINATION FAILURE (after receiving 2 doses of the Moderna COVID-19 Vaccine had 2 blood test and said that has No antibodies what so ever). At the time of the report, VACCINATION FAILURE (after receiving 2 doses of the Moderna COVID-19 Vaccine had 2 blood test and said that has No antibodies what so ever) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 06-May-2021, Blood test: no antibodies found (normal) After two bood test, the patient has no antibodies whatsoever. On an unknown date, Antibody test: negative (Negative) negative.     mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       Treatment medication were not provided. The patient reported that she had underwent blood tests on 06 May 2021 and second date was unknown. The patient reported that she has no antibodies reported after the blood test.  This is a case of vaccination failure (no antibodies response detected) without adverse events. Causality is not applicable.; Sender's Comments: This is a case of vaccination failure (no antibodies response detected) without adverse events. Causality is not applicable.
This case was reported by a consumer via call center representative and described the occurrence of influenza-like symptoms in an adult patient who received SHINGRIX for prophylaxis. Previously administered products included SHINGRIX with an associated reaction of influenza like illness (1st dose, refer case US2018GSK150389). On an unknown date, the patient received the 2nd dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced influenza-like symptoms. Rechallenge with SHINGRIX was positive. On an unknown date, the outcome of the influenza-like symptoms was recovered/resolved. It was unknown if the reporter considered the influenza-like symptoms to be related to SHINGRIX. Additional details were provided as follows: The patient's friend reported this case. The age at vaccination was not reported. The age group was not reported but it was selected as adult as per vaccine indication. The patient experienced flu like symptoms that lasted a day or two. This reporter had not yet received the vaccine. The reporter denied permission to contact their physician. The reporter declined to provide any additional information and said she would tell her friends to call the global response center (GRC). The reporter declined follow up contact. This case has been linked to US2018GSK150388 and US2018145428, reported by the same reporter.
JAW PAIN; EAR ACHE; FELT SICK; CHILLS; VERY BAD HEADACHE; NAUSEA; This spontaneous report received from a patient concerned a 70 year old female. The patient's weight was 157 pounds, and height was 68 inches. The patient's concurrent conditions included: arrhythmias, food allergy, pollen allergy, non alcoholic, non smoker, antibiotic allergy, and erythromycin allergy, and other pre-existing medical conditions included: Patient is not pregnant at the time of vaccination. The patient had no history of drug abuse or Illicit drug usage. The patient experienced drug allergy when treated with epinephrine for heart issues. The patient received covid-19 vaccine (suspension for injection, route of admin not reported, batch number: 1808609, expiry: 09-JUN-2021) dose was not reported, administered on 24-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 24-MAR-2021, the patient experienced jaw pain. On 24-MAR-2021, the patient experienced ear ache. On 24-MAR-2021, the patient experienced felt sick. On 24-MAR-2021, the patient experienced chills. On 24-MAR-2021, the patient experienced very bad headache. On 24-MAR-2021, the patient experienced nausea. The action taken with covid-19 vaccine was not applicable. The patient recovered from jaw pain, ear ache, felt sick, chills, very bad headache, and nausea on 26-MAR-2021. This report was non-serious.
This spontaneous report as received from a pharmacist refers to 3 patients of unknown age. The pharmacist reported that 3 patients developed significant arm swelling after administration of PNEUMOVAX 23 (lot# was not reported) 8 months ago. On an unknown date the patient experienced arm swelling. The outcome of arm swelling was unknown. Additional information has been requested.
Narrative: Patient received his second Covid vaccination on Thursday, 5/6/21. His first shot was given on 4/7/21. Later that day, early Friday, the patient noticed pain in his right calf and hamstring with swelling and engorgement. Patient was diagnosed with acute DVT of femoral vein of right lower extremity. On 5/13/21, patient met with hematologist who noted that this clot, could have been caused by the Covid shot or testosterone induced polycythemia. The hematologist noted that patient's blood work on 5/12/21 "showed no polycythemia although testosterone effect cannot be completely ruled out." He concluded that patient's clot could have been due to a combination of the Covid-19 shot and patient's testosterone therapy. No family history of clotting issues was noted.
Pt recvd MMR vax 2JAN92 & thirteen days following vax pt became irritable & devel a generalized body rash described as small pinpoint dots;
Weakness, debilitating muscle and joint pain, headache, fever, abdominal pain, diarrhea, spreading blister rash on face, neck, chest, knees (back & front), chin, hands
back pain upper and lower back; Chills, fever, headache with heaviness of head; Chills, fever, headache with heaviness of head; Chills, fever, headache with heaviness of head; Chills, fever, headache with heaviness of head; Severe body pain, joint pain; Severe body pain, joint pain; This is a spontaneous report from a contactable consumer. A 47-years-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), dose 1 via an unspecified route of administration, administered in Arm Left on 13Apr2021 12:30 (Lot Number: EW0158) as SINGLE DOSE (at the age of 47 years old) for covid-19 immunisation. Medical history included High cholesterol from an unknown date and unknown if ongoing. Concomitant medications included rosuvastatin (ROSUVASTATIN) 20 mg taken for an unspecified indication, start and stop date were not reported.  The patient previously took Penicillin and experienced allergy; sulfa and experienced allergy. On 14Apr2021 16:00, the patient experienced back pain upper and lower back, Chills, fever, headache with heaviness of head, Severe body pain, joint pain. Patient had to go to emergency room (ER) on the 20Apr2021 since pain and fever was not decreasing. She tested negative for flu, COVID (rapid and pcr), blood work shows no infection and lungs were clear. On 21Apr2021 she still has headache and had to take off from work. ER physician said it is the adverse effect due to the vaccine. The patient underwent lab tests and procedures which included blood test: no infection and lungs were clear on 20Apr2021, body temperature: fever on 19Apr2021, influenza: negative on  20Apr2021 , covid rapid test: negative on 19Apr2021 , COVID (pcr): negative on 20Apr2021.  Therapeutic measures were taken as a result of back pain upper and lower back, Chills, fever, headache with heaviness of head, Severe body pain, joint pain. The events were treated with IV Pain medicine. Outcome of the events was not recovered.
itching here and there form first vaccine; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (itching here and there form first vaccine) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 020B21A and 001C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 31-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PRURITUS (itching here and there form first vaccine). At the time of the report, PRURITUS (itching here and there form first vaccine) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were provided. No treatment information was provided.   This case was linked to MOD-2021-103063 (Patient Link).
After receiving the Pfzier vaccination months later in September I experienced sore throat, and fever only at night. I realized something further may have been going on. My partner contracted COVID 19, and I later was tested and tested negative. I then started to lose my appetite and could no longer take care of myself. The following week I lost my sense of taste and smell.  I then realized I may have contracted COVID 19 from my partner.  I isolated myself for 2 weeks to get better and not spread this to my family.
Severe pain upper Left Shoulder that radiates to neck and elbow. Treated with Medrol Dosepak, and Diclofenec Sodium for pain.
recurrent, worsening, tingling in the left hand, palm & finger, and ended at the wrist; recurrent, worsening, tingling in the left hand, palm & finger, and ended at the wrist; This is a spontaneous report from a contactable consumer. A 33-years-old female patient received bnt162b2 (Pfizer-BioNTech COVID-19 Vaccine, Solution for injection), dose 2 via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as DOSE 2, SINGLE for covid-19 immunisation.  The patient medical history and concomitant medications were not reported. The patient previously received bnt162b2 (Pfizer-BioNTech COVID-19 Vaccine, Solution for injection), dose 1 via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as DOSE 1, SINGLE for covid-19 immunisation and experienced numbness and tingling in both hands, including all fingers. The patient received both doses of the Pfizer-BioNTech COVID-19 Vaccine. A couple of hours after the first dose, Patient experienced numbness and tingling in both hands and all 19 digits, including all fingers. The right hand resolved 3-4 days after the dose and had gradual improvement. Within 2 hours after the second dose, Patient experienced recurrent, worsening, tingling in the left hand, palm & finger, and ended at the wrist. The numbness & tingling did not come back to the right hand. The tingling did not come back in the right hand. The outcome of events was unknown.  Information on the lot/batch number has been requested. further information has been requested.
Golf ball sized firm, tender nodule noted in right lateral breast on 4/2 at approximately 9pm.  Right sided scalp tenderness with hair brushing noted on 4/4 at 4pm. Right ear pain, pain on right side of tongue posteriorly, and pain with swallowing noted on 4/5 at approximately 8am.
My left shoulder is a little sore where I received the vaccine; I also feel cold as if a fever is coming on.; Body hurts; Dose number 3; This is a spontaneous report from a contactable reporter (consumer or other non-HCP). The reporter is the patient.  A 50-year-old male patient received bnt162b2 (BNT162B2), administered in left arm , administration date 09Dec2021 at 16:00 (Lot number: unknown) at the age of 50 years as dose 3 (booster), single for COVID-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE, Lot Number: EP6955,vaccine location: Left arm, Administration time: 10:30), administration date: 04Mar2021, when the patient was 49 years old, for COVID-19 immunisation and Bnt162b2 (DOSE 2, SINGLE, Lot Number: EL3247,vaccine location: Right arm, Administration time: 10:30), administration date: 25Mar2021, when the patient was 49 years old, for COVID-19 immunisation.  The following information was reported: IMMUNISATION (non-serious) with onset 09Dec2021 at 16:00, outcome "unknown", described as "Dose number 3"; ARTHRALGIA (non-serious) with onset 10Dec2021 at 05:00, outcome "not recovered", described as "My left shoulder is a little sore where I received the vaccine"; FEELING COLD (non-serious) with onset 10Dec2021 at 05:00, outcome "not recovered", described as "I also feel cold as if a fever is coming on"; PAIN (non-serious) with onset 10Dec2021 at 05:00, outcome "not recovered", described as "Body hurts". Therapeutic measures were not taken as a result of arthralgia, feeling cold and pain.  Additional Information: The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to COVID vaccine. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care.  The lot number for BNT162b2 was not provided and will be requested during follow up.
Prolonged crying - 6 hours; Extremely irritable; Local swelling at the site of 2 injections (right upper ant. thigh)
PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE EPILEPSY, GENERALIZED IDIOPATHIC CLONIC EPILEPSY EPILEPSY, UNSPECIFIED REVERSIBLE ISCHEMIC NEUROLOGIC DEFICIT SYNDROME HYPOTENSION 7/8/2022 &  8/20/2022  --  HOSP- HOSPITAL